PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Saama’s Drug Efficacy and Patient Safety Analytics one of 2019’s Most Innovative Products. This is the third year in a row that Saama has received recognition in PM360’s Innovation issue; Saama was named one of PM360’s Most Innovative Companies in 2018, and Saama’s Life Science Analytics Cloud (LSAC) was named one of the Most Innovative Products of 2017.
PM360 presents the 2019 Innovators here. Below are a few key points from PM360’s article about Saama (click here to read more):
“In February 2019, Saama Technologies unveiled a new machine learning-based capability to extend the existing abilities of its award-winning Life Science Analytics Cloud (LSAC), which was launched in 2017. Drug Efficacy and Patient Safety Analytics is a new, state-of-the-art functionality for LSAC that is infused with AI to exponentially streamline the time and effort traditionally required to correlate patient profiles with data variables.”
“Drug Efficacy and Patient Safety Analytics supports indication-specific, pre-trained models to identify riskier patients. And Drug Efficacy and Patient Safety Analytics makes it easier to monitor patient safety and assess the efficacy of the drug being tested, enabling researchers to identify previously undetectable patient deviations, as well as potential corresponding safety and efficacy issues, sooner than ever before.”
“Going forward, Drug Efficacy and Patient Safety Analytics will also become an integral part of the Clinical Insights solution formulated after Saama’s acquisition of Comprehend Systems, Inc.”